Although the application of nanomedicine in cancer therapy has been explored,[50, 51, 52] this study represents one of the first applications of a nanodrug targeting CD73 specifically in EGFR‐mutant lung cancer, providing a promising strategy to counteract the immunosuppressive TME and improve responses to ICIs in this hard‐to‐treat patient population. Here, EGFR is linked to lung carcinoma.